Author: Eunoia Consulting Co. | Published: September 7, 2026
A practical healthcare AI inventory makes ownership, intended use, data classes, human review, risk tiers, assurance evidence, and change triggers visible before informal technology use becomes unmanaged shadow AI.
Healthcare leaders rarely set out to create shadow AI. It usually emerges through small, plausible decisions: a team trials a transcription tool, a department adopts a new analytics module, a vendor enables a generative feature by default, or an employee starts using a public assistant to prepare operational materials. Each decision may feel local. Together, they create a portfolio of systems that leadership cannot confidently describe, assess, monitor, or retire.
An AI inventory is the practical answer. It is not a spreadsheet kept for compliance theatre, nor a procurement archive that stops at signature. It is an active operating record of where AI is used, what it is allowed to do, which information it touches, who is accountable, and when its risk posture must be reconsidered. The National Institute of Standards and Technology (NIST) frames AI risk management as a continuous set of Govern, Map, Measure, and Manage activities rather than a one-time approval exercise.[1] An inventory gives those activities somewhere to begin.
Traditional software inventories often answer a narrow question: what applications do we own? An AI inventory must answer a broader operational question: what decisions, recommendations, summaries, predictions, or generated outputs are affecting staff, patients, members, or business processes?
That distinction matters because an AI capability may sit inside a familiar system. An EHR module, scheduling platform, patient communications tool, revenue-cycle product, imaging workflow, or contact-centre platform may add machine-learning or generative functionality without looking like a separate application. The risk can also change when a vendor updates the model, shifts the hosting architecture, modifies its retention practice, expands integrations, or adds a new action-taking feature.
NIST’s AI RMF and its Generative AI Profile emphasise governance across the AI lifecycle, including understanding context, documenting capabilities and limitations, assessing risks, and managing them over time.[1] [2] The inventory should therefore capture the actual use of a system, not only the name on a contract.
Many organisations delay this work because they imagine a large enterprise exercise. A more useful first step is a short discovery sprint with clear boundaries. Ask each function to identify tools that generate content, classify information, recommend an action, prioritise work, predict a result, recognise images or speech, or automate a workflow using a model.
The aim is candour. Staff are more likely to disclose informal use when the first conversation is framed as risk understanding and enablement rather than punishment. A good discovery prompt includes approved enterprise tools, vendor features, team subscriptions, pilots, embedded assistants, automated workflows, and any manually copied information used with an external tool.
The initial record will be incomplete. That is normal. The more important failure is maintaining the fiction that only centrally purchased tools exist. Leaders should make the inventory easy to update, appoint an owner for intake, and publish a clear route for teams to ask whether a proposed use needs review.
An inventory should support a decision, not merely satisfy a reporting request. The following fields are a practical minimum.
| Inventory field | Why it matters | Example question | | --- | --- | --- | | System and vendor name | Establishes an unambiguous record | What product, module, and vendor are in use? | | Business owner and clinical sponsor | Creates accountable ownership | Who can approve changes or pause use? | | Intended use and user group | Defines the permitted operating boundary | Is it drafting notes, triaging work, supporting coding, or communicating with patients? | | Model or feature version | Makes change management possible | Which model, release, or enabled AI feature is operating? | | Inputs, outputs, and data classes | Identifies privacy, quality, and safety implications | Does the tool receive ePHI, operational data, public information, or free text? | | Integration and action scope | Reveals whether the system only advises or can act | Can it write back to a record, send a message, or alter a queue? | | Human-review point | Makes meaningful oversight auditable | Who reviews the output, at what point, and with what authority to override? | | Risk tier and rationale | Prioritises attention | What could happen if an output is wrong, delayed, biased, unavailable, or misused? | | Assurance evidence | Links the record to verification | What validation, security review, contract, or monitoring evidence exists? | | Review and renewal dates | Prevents stale approvals | What event or date triggers reassessment? |
The most valuable fields are often the ones that force ambiguity into the open. “AI-enabled communications” becomes more actionable when the record states whether the tool drafts staff-facing messages, sends patient-facing content automatically, uses appointment data, or has a human approval step.
Shadow AI thrives when nobody is clearly accountable. The system owner should be responsible for the day-to-day use case, adoption, and issue reporting. A clinical or operational sponsor should be responsible for whether the workflow fits the organisation’s care or service model. A governance function should set the review standard, maintain the register, and escalate patterns that cross departments.
Those roles do not need to create a slow committee for every low-risk productivity feature. They do need to create a clear path for a higher-impact use case. For example, an internal drafting assistant with no protected or sensitive inputs may warrant lightweight review and workforce guidance. A tool that proposes clinical content, prioritises patients, influences access, or writes data into a core system requires a more deliberate assessment of intended use, users, reliability, possible failures, and override arrangements.
This is where an AI governance programme becomes operational rather than aspirational. It gives the inventory a decision framework, escalation route, and recurring review cadence.
An approved tool is not permanently approved. New model versions, new data connections, expanded user groups, new geographies, altered retention terms, and newly enabled autonomous actions can change the risk profile. The inventory should include change triggers that automatically prompt a reassessment.
Useful triggers include a material vendor release, an incident or near miss, a new data type, an integration change, a complaint pattern, an annual renewal, a shift from draft-only to action-taking use, or a change in the population affected. The review does not always need to restart from zero. It should, however, record what changed, who assessed it, and what decision followed.
NIST’s Govern function is particularly helpful here because it focuses on policies, processes, roles, and organisational culture that enable risk management throughout the lifecycle.[1] In practice, that means an inventory is connected to procurement, security review, clinical or operational quality review, training, incident management, and contract renewal—not held apart from them.
The inventory should not become a document known only to a central committee. Teams need practical guidance: which tools are approved, which uses are prohibited or restricted, what information may be entered, when human review is required, and where to report an unexpected output or concern.
Visibility also strengthens adoption. A team is less likely to seek an unapproved shortcut when it can find a sanctioned alternative and understands the process for proposing a new use. Regular, non-punitive communications can share lessons from reviews without exposing sensitive details: for example, why an integration was delayed, why a pilot was limited to a particular workflow, or why a seemingly simple feature needs a revised data-flow assessment.
Start with the systems already closest to decision-making, patient communication, documentation, access, and sensitive data. Within 30 days, a leadership team can usually build a credible first register, classify the most consequential gaps, and establish a repeatable intake process. The objective is not to eliminate responsible experimentation. It is to ensure that innovation remains visible, owned, and governable.
Eunoia Consulting Co. helps healthcare organisations translate AI governance principles into practical inventories, approval pathways, and operating controls. If you are formalising oversight across a growing technology portfolio, speak with our AI governance team about a programme that fits your organisation’s scale and risk profile.
This article was produced by the Eunoia Consulting Co. Editorial Team. Eunoia Consulting Co. specialises in AI governance, healthcare operations, and data strategy for healthcare and veterinary organisations.
[1] NIST, AI Risk Management Framework
[2] NIST, Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile